SecBot SecBot
Biotech Drug Report Generated Oct 31, 2026

ABBV-382

ABBV·AbbVie Inc.
NEUTRAL
Drug Impact Rating3/10
Trial phase
Phase 2
Time to market
Multiple years away from potential approval. The IBD combination is in Phase 2b with AbbVie evaluating Phase 3 acceleration options, meaning an approved product is likely 5+ years away if development continues successfully. The HIV program faces a more uncertain path given mixed Phase 2 results.
Why 3/10
ABBV-382 is a Phase 2 asset in a massive, diversified pipeline at AbbVie (a ~$295B market cap company with $10B+ H1 2026 Skyrizi revenue alone). No imminent dated binary catalyst (PDUFA or pivotal readout) is scheduled in the next ~12 months. The Phase 2a TARGET-CD results were just reported on October 19, 2026, and the next catalyst is the Phase 2b platform study readout has no announced date. Even positive data would move AbbVie shares only modestly given the company's scale.
Actionable Insight NEUTRAL

The next catalyst for ABBV-382 is the ongoing Phase 2b platform basket study (M26-266) evaluating Skyrizi + ABBV-382 in Crohn's disease and ulcerative colitis, which began enrollment in July 2026. No specific readout date has been announced. AbbVie has indicated it is evaluating Phase 3 acceleration options for the IBD combination, so a Phase 3 start announcement could be a positive catalyst. The HIV program's mixed Phase 2 results make further development in that indication uncertain.

Price Chart

Loading chart...

Executive Summary

ABBV-382 (trosunilimab) is AbbVie's investigational anti-alpha4beta7 integrin monoclonal antibody being developed in two distinct areas: as part of a functional HIV cure strategy (in combination with budigalimab) and as a next-generation inflammatory bowel disease therapy (combined with Skyrizi as ABBV-466). Phase 2a TARGET-CD results presented October 19, 2026 at UEG Week showed the Skyrizi + ABBV-382 combination achieved 30.2% endoscopic remission at Week 12 versus 21.3% for Skyrizi alone and 18% for ABBV-382 alone, with rates rising to 40.5% by Week 24. In HIV, Phase 2 results from CROI 2026 (February 2026) showed the budigalimab + trosunilimab combination delayed viral rebound in about a quarter of patients after stopping antiretroviral therapy, but did not prevent rebound long-term. Both programs remain in Phase 2, and ABBV-382 is a small part of AbbVie's massive, diversified pipeline.

How It Works

ABBV-382 is a monoclonal antibody (a lab-made protein that acts like a natural antibody) that targets and blocks alpha4beta7 integrin, a protein on the surface of certain immune cells that helps them travel to the gut. By blocking this protein, the drug aims to reduce gut inflammation (in Crohn's disease/ulcerative colitis) and also interfere with HIV's ability to infect cells and hide in the body (for HIV functional cure).

Trial Status

ABBV-382 is in Phase 2 development across two indications. For Crohn's disease, the Phase 2a TARGET-CD trial (NCT06548542, ~300 patients) met its primary endpoint in October 2026, showing the Skyrizi combination (ABBV-466) outperformed both monotherapies. A larger Phase 2b platform basket study (M26-266) began enrolling in July 2026, evaluating the combination in both Crohn's disease and ulcerative colitis. For HIV, a Phase 2 study (NCT06032546, 163 patients randomized across six arms) testing budigalimab + ABBV-382 was completed and results were presented at CROI 2026 in February 2026, showing delayed but not prevented viral rebound after ART interruption.

The Two-Sided Case

▲ Bull Case4
The Skyrizi + ABBV-382 combination (ABBV-466) showed compelling Phase 2a data showing 30.2% endoscopic remission at Week 2 (vs 21.3% for Skyrizi alone and 18% for ABBV-382 alone), with rates rising to 40.5% by Week 24, suggesting a clear additive benefit from dual mechanism targeting.
AbbVie is accelerating Phase 3 development plans for the IBD combination, indicating internal confidence in the asset's potential to extend Skyrizi's franchise life.
The HIV functional cure approach addresses a large unmet need (38 million people living with HIV globally) and the Phase 2 showed delayed viral rebound in about a quarter of patients, providing proof of mechanism.
AbbVie's strong commercial infrastructure and Skyrizi's existing $10B+ revenue base provide a clear commercialization path for the IBD combination if approved.
▼ Bear Case4
ABBV-382 is one of many pipeline programs at a mega-cap pharma company; even successful Phase 3 data would have a modest impact on AbbVie's share price given the company's scale and diversified revenue base.
The HIV functional cure data was mixed: the combination delayed but did not prevent viral rebound long-term, and the path to a true functional cure remains uncertain.
The IBD space is highly competitive with multiple approved therapies (Skyrizi, Stelara, Entyvio, Rinvoq, Remicade biosimilars) and the combination will need to show clear differentiation to justify premium pricing.
The Phase 2a TARGET-CD trial was relatively small (~300 patients) and the 30.2% remission rate, while beating monotherapy, still leaves most patients not achieving remission.

Upcoming Catalysts

  • Phase 2b platform basket study (M26-266) readout in Crohn's disease and ulcerative colitis - no date announced
  • Potential Phase 3 start announcement for Skyrizi + ABBV-382 in IBD
  • Further HIV functional cure data updates

Source Filing

The SecBot filing or press-release report that triggered this drug report:

AbbVie Inc. 8-K ABBV ·Originating report

Sources · 12

Hover a chip for the title
1 investors.abbvie.com2 biospace.com3 aidsmap.com4 adisinsight.springer.com5 croiconference.org6 croiconference.org7 firstwordpharma.com8 varese-group.com9 investors.abbvie.com10 natap.org11 sec.gov12 allsci.com